Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Trevogrumab?
Plain language first. The technical label stays, but it never stands alone.Overview
It is an attempt to make weight loss come more from fat. It is not approved anywhere, and it is an antibody rather than a peptide.
Trevogrumab is an antibody that blocks myostatin, the signal that limits muscle growth. It is being tested alongside semaglutide for the same reason as apitegromab: about a third of the weight lost on semaglutide is muscle.
What it's used for
An experimental antibody given alongside semaglutide, to lose more fat and less muscle.
How does Trevogrumab work?
What it does in the body, and where.Trevogrumab blocks myostatin, the brake on muscle growth. The interesting part of this trial is what happened when a second brake was blocked at the same time.
- 01Semaglutide takes muscle along with fatThe trial measured it directly: about a third of the weight lost on semaglutide alone was muscle, not fat.
- 02Blocking myostatin prevents about half of thatAt 200 mg it preserved 50.8% of the muscle that would have been lost, and at 400 mg, 51.3%. Doubling the dose changed almost nothing.
- 03Blocking a second signal preserved more, and cost moreAdding garetosmab, which blocks a related signal called activin A, preserved 80.9%. But dropouts jumped from under 10% to 28.3%, and two people died.
- 04More is not automatically betterThis is the clearest example in the category. The best result on paper came from the arm with the worst safety, and the company has not linked the deaths to the drug either way.
Where this compound is thought to act.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Keeping muscle during weight loss on semaglutide, where about half the usual muscle loss was prevented at either doseInvestigational
- Holding onto weight-loss results after the losing phase, which the trial is still testingInvestigational
The published record
Papers and trials about Trevogrumab
12 papers tagged human · 1 not reviews or lab · 0 clinical trial publications
8 registered trials · none with posted results
Furthest stage reached: Phase 2, completed, no results posted
Compare this against the whole library →
Prohibited at all times, in and out of competition. S4.3 Myostatin inhibitors; the list names other myostatin-neutralizing antibodies and covers the class. Non-Specified.RegulatorsCounted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Trevogrumab
Evidence
Investigational
Category
Muscle building
Common vial
Varies
Half-life
Not established
How much, and do you cycle it?
The range, and whether you take breaks.200 or 400 mg (trial doses), in the trial schedule. Given through a 26-week weight-loss phase, then a 26-week holding phase Trial dose
The trial design splits into losing weight and then keeping it off. The second half is testing whether the drug alone holds the result, and those results are not out yet.
Not establishedNo figure
No numeric human half-life has been disclosed. Antibodies of this class typically run around 21 days, but that is a class expectation rather than a measurement of this one.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Given by infusion in a trial rather than sold as a vial, so no draw can be shown.
Trevogrumab starts at $194.95 across 1 vendor.
1 listing, last read Oct 10, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Trevogrumab keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.This is not something you can buy or mix. It is given in a clinic as part of a trial, and there is no vial size or syringe draw, so the calculator does not apply. Two doses have been tested, 200 mg and 400 mg, and they performed almost the same.
Who should avoid it
- Not available outside a clinical trial
- Pregnancy
- No safety record outside the trial setting
Stop and get help
- Signs of an allergic reaction during or after an infusion
- Anything unusual, since the safety record is short
Common effects
- On its own with semaglutide it was generally well tolerated, with 4% to 10% of people stopping early
- Added to a second antibody called garetosmab, 28.3% stopped early
- Two deaths happened in that three-drug group, one from an undetermined cause and one from cardiac arrest, both in people with existing heart risk. The company has not found a link to the treatment
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Trevogrumab approved?
And where the numbers on this page come from.No. Trevogrumab is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteInto a vein
- Checked22 September 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Not approved anywhere. Regeneron has stated that the safety and effectiveness of trevogrumab have not been assessed by any regulator. The trial is still running: after 26 weeks of weight loss, people move into a 26-week phase to see whether the drug holds the result.
What regulators say
From official documentsProhibited at all times, in and out of competition. S4.3 Myostatin inhibitors; the list names other myostatin-neutralizing antibodies and covers the class. Non-Specified.
Checked 12 September 2026WADA: The 2026 Prohibited List (in force 1 January 2026)
You can compare this against the whole library, or read how to check a seller.
What else is like Trevogrumab?
Others in Muscle building, side by side.If you're weighing Trevogrumab, it's worth reading ACE-083, Apitegromab, and Bimagrumab in the same class.
A myostatin antibody trialled with semaglutide, where the three-drug version got dangerous.
- Dose
- 200 or 400 mg (trial doses)
- How often
- In the trial schedule
A muscle drug injected into one muscle at a time. It grew muscle and changed nothing functional.
- Dose
- 200 to 240 mg into one named muscle, in the trial
- How often
- Every 3 weeks in the trial
An antibody tested to stop GLP-1 weight loss taking muscle along with fat.
- Dose
- 10 mg/kg per month (trial dose)
- How often
- Monthly
An experimental shot that strips fat while adding muscle.
- Dose
- 10 up to 30 mg/kg per month (trial doses)
- How often
- Monthly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- Why Does My Peptide Injection Itch or Welt
Injection-site irritation, a histamine reaction, or a true allergy, and how to tell them apart.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
Sources
- Regeneron, complete 26-week Phase 2 COURAGE results, presented at EASD(2025)33% of semaglutide-induced weight loss was lean mass. Adding trevogrumab prevented about half of it. The triplet arm had substantially higher discontinuation and two deaths, with no causal link established.
- Regeneron, interim Phase 2 COURAGE results(2025)Lean mass preserved: 50.8% at trevogrumab 200 mg, 51.3% at 400 mg, 80.9% with garetosmab added. Semaglutide alone lost 7.9 lb of lean mass.
Beyond these, 15 records are indexed. Browse the records